Trial reportAIDS care2025
People who inject drugs and men who have sex with men living with HIV in India experience low probability of viral rebound and high levels of persistent viremia during the first 12 months of antiretroviral therapy.
Trial report in AIDS care, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acceptability and Preferences of Long-Acting Injectable Pre-Exposure Prophylaxis and Antiretroviral Therapy Among Men Who Have Sex With Men and People Who Inject Drugs in India: Insights for Future Implementation.Journal of the International AIDS Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
People who inject drugs (PWID) and men who have sex with men (MSM) in India are disproportionately affected by HIV and experience challenges achieving sustained viral suppression. We evaluated probabilities of suppression over time and characteristics associated with persistent viremia and viral rebound among MSM and PWID living with HIV (PLHIV) using 12 months of data collected between 2017-2019 from a cluster-randomized trial across 16 cities in India. To assessprobabilities of suppression, we fit logistic transition models with generalized estimating equations. To assess correlates of persistent viremia and viral rebound, we fit multivariable multilevel logistic regression models. Of 750 PWID, 88% were male and 14% completed high school. Of 850 MSM, 29% completed high school and 54% were married. 46% of PWID and 67% of MSM maintained viral suppression once achieved. Probabilities of viral rebound decreased over time. The probability of newly achieving suppression decreased, from 33%-12% after six months among PWID and 60%-13% among MSM. Among PWID, correlates of persistent viremia included lower education, employment, homelessness, and active injection. Among MSM, hazardous alcohol use was associated with viremia and viral rebound. Treatment engagement and support efforts need to be intensified to encourage PLHIV to achieve life-long suppression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.